West Pharmaceutical Services (NYSE:WST) Reaches New 1-Year High – Here’s Why

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $402.50 and last traded at $399.7950, with a volume of 57,498 shares traded. The stock had previously closed at $398.29.

Key Stories Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Quarterly results exceeded expectations. West reported adjusted EPS of $2.66, ahead of the $2.20 analyst consensus, while revenue rose 8.7% year over year to $874.5 million, topping the $827.1 million estimate. Reported diluted EPS increased 57.3% to $3.02. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 guidance. Full-year revenue guidance increased to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion, while adjusted diluted EPS guidance rose to $9.38-$9.48 from $8.85-$9.05. The guidance now slightly exceeds prevailing expectations. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: High-value products remained the key growth engine. High-Value Product Components sales climbed 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and signaling continued demand for West’s higher-profit pharmaceutical packaging and components. West Pharma Q3 Earnings Rise on HVP Strength

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Barclays upped their target price on West Pharmaceutical Services from $400.00 to $440.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Evercore reaffirmed an “outperform” rating and set a $425.00 price target on shares of West Pharmaceutical Services in a research report on Monday, July 27th. UBS Group lifted their price target on West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Finally, Citigroup boosted their price objective on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Twelve investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $391.17.

West Pharmaceutical Services Trading Up 3.2%

The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The firm has a market cap of $29.32 billion, a P/E ratio of 53.34, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. The firm’s 50-day simple moving average is $366.60 and its 200 day simple moving average is $312.50.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.20 by $0.46. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $874.50 million during the quarter, compared to the consensus estimate of $827.12 million. During the same period in the prior year, the firm earned $1.96 EPS. The company’s revenue was up 8.7% compared to the same quarter last year. As a group, analysts expect that West Pharmaceutical Services, Inc. will post 8.92 earnings per share for the current year.

West Pharmaceutical Services Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 18th. Investors of record on Wednesday, November 11th will be paid a $0.26 dividend. The ex-dividend date is Tuesday, November 10th. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.22. This represents a $1.04 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.27%.

Insiders Place Their Bets

In other West Pharmaceutical Services news, VP Annette Favorite sold 8,135 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total value of $2,772,489.35. Following the completion of the sale, the vice president directly owned 16,845 shares of the company’s stock, valued at $5,740,944.45. This trade represents a 32.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold 15,659 shares of company stock worth $5,443,749 over the last three months. 0.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On West Pharmaceutical Services

Several large investors have recently added to or reduced their stakes in the company. Integrity Alliance LLC. bought a new position in shares of West Pharmaceutical Services in the third quarter worth $212,000. Aware Super Pty Ltd as trustee of Aware Super bought a new stake in West Pharmaceutical Services during the third quarter valued at $22,802,000. Bank Julius Baer & Co. Ltd Zurich grew its position in West Pharmaceutical Services by 39.8% during the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 10,169 shares of the medical instruments supplier’s stock worth $3,791,000 after buying an additional 2,893 shares in the last quarter. Virtue Capital Management LLC grew its position in West Pharmaceutical Services by 30.5% during the third quarter. Virtue Capital Management LLC now owns 1,009 shares of the medical instruments supplier’s stock worth $374,000 after buying an additional 236 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in West Pharmaceutical Services during the third quarter worth about $8,999,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.